Results 91 to 100 of about 3,975 (165)

A case of HIV encephalopathy with HIV cerebrospinal fluid escape, followed by second-generation integrase inhibitor resistance

International Journal of Infectious Diseases
The management of advanced HIV can be complicated by immune reconstitution inflammatory syndrome (IRIS) and cerebrospinal fluid (CSF) viral escape.
Wen Wang, Jun Yang, Ziqiu Wang, Ying Wen
doaj   +1 more source

Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380–1490) : a randomised, double-blind, multicentre, phase 3, non-inferiority trial

, 2017
International audienceIntegrase strand transfer inhibitors (INSTIs) coadministered with two nucleoside or nucleotide reverse transcriptase inhibitors (NRTIs) are recommended as first-line treatment for HIV, and coformulated fixed-dose combinations are ...
SenGupta, Devi, Anton Pozniak, Koenig, Ellen, Edwin DeJesus, Andrew Cheng, Joseph Custodio, Workowski, Kimberly, Hans-Jürgen Stellbrink, Sax, Paul, DeJesus, Edwin, Antinori, Andrea, Cheng, Andrew, Paul E Sax, Ellen Koenig, Kirsten White, Reynes, Jacques, M Luisa Montes, Slim, Jihad, Jihad Slim, Will Garner, Custodio, Joseph, Jacques Reynes, Stellbrink, Hans-Jürgen, Erin Quirk, Montes, M Luisa, Garner, Will, Kimberly Workowski, Andrea Antinori, White, Kirsten, Devi SenGupta, Quirk, Erin, Pozniak, Anton   +31 more
core   +1 more source

The Study of the Complexation of Calix[4]arene-Hydroxymethylphosphonic Acid and Calix[4]arene-Hydroxymethyldimethylphosphine Oxide with Antiviral Drugs

Журнал органічної та фармацевтичної хімії
The host-guest complexation of cone-shaped calix[4]arene-hydroxymethylphosphonic acid (CPA) and calix[4]arene-hydroxymethyldimethylphosphine oxide (CPO) with active pharmaceutical ingredients of antiviral drugs Remdesivir, Nevirapine, Vesatolimod, and ...
Olga I. Kalchenko, Serhii O. Cherenok, Anna I. Selikhova, Pilar López-Cornejo, Andrii B. Drapailo, Vitaly I. Kalchenko   +5 more
doaj   +1 more source

Abstracts From AIDS 2026, the 26th International AIDS Conference, 26 – 31 July 2026 Rio de Janeiro, Brazil & virtual

Journal of the International AIDS Society, Volume 29, Issue S4, July 2026.
wiley   +1 more source

Fetal Defects in Mice Treated with Integrase Strand Transfer Inhibitors: Comparison of Dolutegravir, Raltegravir, Bictegravir and Cabotegravir

Background: Integrase strand transfer inhibitors (INSTIs) are preferred for treatment of HIV. However, safety data in pregnancy are limited for newer INSTIs.
Nguyen, Jessica, Yee, Audrey, Sanghvi, Tanvi, Copp, Andrew J, Serghides, Lena, Mohan, Haneesha, Tejada, Oscar, Jao, Jennifer, Greene, Nicholas DE, Sled, John G, Laurette, Evelyn Yukino   +10 more
core   +1 more source

Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV: a phase 2/3, open-label, single-arm study

BACKGROUND: Coformulated bictegravir, emtricitabine, and tenofovir alafenamide is a single-tablet regimen and was efficacious and well tolerated in children and adolescents with HIV (aged 6 years to \u3c18 years) in a 48-week phase 2/3 trial.
Rakhmanina, Natella, HellstrÖm, Elizabeth, Hindman, Jason T, Natukunda, Eva, Gaur, Aditya H, Leisegang, Rory, Rodriguez, Carina A, Strehlau, Renate, Kersey, Kathryn, Lalloo, Umesh, Kosalaraksa, Pope, Liberty, Afaaf, Vieira, Vinicius A, Cunningham, Coleen K, Venter, Esme L, Cotton, Mark F, Kaur, Meenu, McGrath, Eric J, Rungmaitree, Supattra   +18 more
core   +1 more source

Pharmacogenetics of dolutegravir and bictegravir plasma and intracellular pharmacokinetics

Purpose: The aim of this study was to investigate the impact of important polymorphisms in pharmacogenes on plasma and intracellular pharmacokinetics of dolutegravir and bictegravir.
Elens, Laure, Delongies, Kévin-Alexandre, Haufroid, Vincent, Comets, Emmanuelle, De Greef, Julien, Lemaitre, Florian, Panin, Nadtha, Belkhir, Leïla, 20th European AIDS Conference 2025, Vincent, Anne, Vandercam, Bernard, Yombi, Jean Cyr   +11 more
core  

Hepatitis B Virus Reactivation after Switch to Cabotegravir/Rilpivirine in Patient with Low Hepatitis B Surface Antibody

Emerging Infectious Diseases
A patient in Japan with HIV began antiretroviral therapy because of acute hepatitis B virus (HBV) 15 years ago, with low hepatitis B surface antibody, and experienced breakthrough HBV reactivation 4 months after switching from bictegravir/emtricitabine ...
Eisuke Adachi, Ayako Sedohara, Kotaro Arizono, Kazuaki Takahashi, Amato Otani, Yoshiaki Kanno, Makoto Saito, Michiko Koga, Hiroshi Yotsuyanagi   +8 more
doaj   +1 more source

Application of bictegravir/emtricitabine/tenofovir alafenamide in rapid initiation of antiretroviral therapy: a review

Zhongguo gonggong weisheng
Rapid initiation of antiretroviral therapy (rapid ART) has multiple clinical benefits, such as increasing the rates of treatment initiation, retention in care, and virologic suppression, and reducing the mortality rate.
Rentian CAI, Fang ZHENG, Hongxia WEI
doaj   +1 more source

Bictegravir Use During Pregnancy: A Multicenter Retrospective Analysis Evaluating Human Immunodeficiency Virus Viral Suppression and Perinatal Outcomes

This study describes the largest cohort to date (n = 147) of pregnant patients with human immunodeficiency virus (HIV) on bictegravir (BIC). BIC in pregnancy was associated with high levels of viral suppression and perinatal outcomes similar to those in ...
Holt, Lauren M., Duthely, Luthita, Short, William R., Duque, Alejandra, Hyun, Eleanor, Badell, Martina L., Morales, Andrea Lugo, Druyan, Brian, McKinney, Jennifer, Sheth, Anandi N., Momplaisir, Florence, Ndubizu, Chima, Joseph, Naima   +12 more
core   +1 more source